Company Filing History:
Years Active: 1989
Title: Shizuo Kozasa – Innovator in Antiallergic and Anti-Inflammatory Agents
Introduction
Shizuo Kozasa is a notable inventor based in Suita, Japan, recognized for his contributions to the field of pharmaceuticals, particularly in the development of antiallergic and anti-inflammatory compounds. His innovative spirit led him to create a unique derivative that has potential therapeutic applications.
Latest Patents
Kozasa holds a patent for the invention titled "Antiallergic and antiinflammatory benzothiazolinone derivatives." This patent encompasses benzothiazolone derivatives represented by a specific chemical formula, where various substituents are defined, including halogen, alkylene, and functional groups such as alkoxy and amino. These compounds are noted for their efficacy as antiallergic and anti-inflammatory agents, providing a significant advancement in pharmaceutical research.
Career Highlights
Throughout his career, Shizuo Kozasa has been associated with prominent organizations, including Hoei Pharmaceutical Co., Ltd. and the Research Institute for Production Development. His work in these institutions has been pivotal in the exploration of new drug formulations, showcasing his dedication to enhancing public health through innovative solutions.
Collaborations
Kozasa's collaborations with esteemed colleagues such as Suminori Umio and Takahiro Yabuuchi have further honed his research capabilities. Working alongside such talented individuals has enabled him to foster innovative ideas and refine his inventions within the pharmaceutical industry.
Conclusion
In summary, Shizuo Kozasa exemplifies the role of a forward-thinking inventor in the pharmaceutical sector. With a patented innovation aimed at addressing allergies and inflammation, his work continues to pave the way for future advancements in medicine. His collaborative efforts and experience at reputable companies highlight his commitment to improving the quality of life through targeted therapeutic inventions.